Adelaide Research & Scholarship: Search

Search

Results 1-10 of 10 (Search time: 0.003 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2016	Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer	Liu, G.; Tu, D.; Lewis, M.; Cheng, D.; Sullivan, L.; Chen, Z.; Morgen, E.; Simes, J.; Price, T.; Tebbutt, N.; Shapiro, J.; Jeffery, G.; Mellor, J.; Mikeska, T.; Virk, S.; Shepherd, L.; Jonker, D.; O'Callaghan, C.; Zalcberg, J.; Karapetis, C.; et al.
	2014	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer	Jonker, D.; Karapetis, C.; Harbison, C.; O'Callaghan, C.; Tu, D.; Simes, R.; Malone, D.; Langer, C.; Tebbutt, N.; Price, T.; Shapiro, J.; Siu, L.; Wong, R.; Bjarnason, G.; Moore, M.; Zalcberg, J.; Khambata-Ford, S.
	2015	Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature	Chan, D.; Pavlakis, N.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Segelov, E.; Rosell, R.
	2013	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.	Siu, L.; Shapiro, J.; Jonker, D.; Karapetis, C.; Zalcberg, J.; Simes, J.; Couture, F.; Moore, M.; Price, T.; Siddiqui, J.; Nott, L.; Charpentier, D.; Liauw, W.; Sawyer, M.; Jefford, M.; Magoski, N.; Haydon, A.; Walters, I.; Ringash, J.; Tu, D.; et al.
	2013	Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17	Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
	2012	Management of advanced gastric cancer	Price, T.; Shapiro, J.; Segelov, E.; Karapetis, C.; Pavlakis, N.; Van Custem, E.; Shah, M.; Kang, Y.; Tebbutt, N.
	2013	Current opinion on optimal treatment for colorectal cancer	Price, T.; Segelov, E.; Burge, M.; Haller, D.; Ackland, S.; Tebbutt, N.; Karapetis, C.; Pavlakis, N.; Sobrero, A.; Cunningham, D.; Shapiro, J.
	2014	The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials	Segelov, E.; Chan, D.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Pavlakis, N.
	2016	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015	Price, T.; Thavaneswaran, S.; Burge, M.; Segelov, E.; Haller, D.; Punt, C.; Arnold, D.; Karapetis, C.; Tebbutt, N.; Pavlakis, N.; Gibbs, P.; Shapiro, J.
	2010	Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: Report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008	Price, T.; Tebbutt, N.; Karapetis, C.; Segelov, E.; Pavlakis, N.; Cunningham, D.; Sobrero, A.; Haller, D.; Shapiro, J.